LYRA THERAPEUTICS INC (LYRA)
US55234L1052 - Common Stock
Overall LYRA gets a fundamental rating of 3 out of 10. We evaluated LYRA against 194 industry peers in the Pharmaceuticals industry. The financial health of LYRA is average, but there are quite some concerns on its profitability. LYRA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LYRA had negative earnings in the past year.
In the past year LYRA has reported a negative cash flow from operations.
LYRA had negative earnings in each of the past 5 years.
In the past 5 years LYRA always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -107.20%, LYRA is doing worse than 79.17% of the companies in the same industry.
LYRA's Return On Equity of -327.30% is on the low side compared to the rest of the industry. LYRA is outperformed by 78.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.2% | ||
| ROE | -327.3% | ||
| ROIC | N/A |
ROA(3y)-57.82%
ROA(5y)-61.94%
ROE(3y)-88.45%
ROE(5y)-103.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LYRA has been increased compared to 1 year ago.
Compared to 5 years ago, LYRA has more shares outstanding
There is no outstanding debt for LYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
LYRA has an Altman-Z score of -7.49. This is a bad value and indicates that LYRA is not financially healthy and even has some risk of bankruptcy.
LYRA has a Altman-Z score of -7.49. This is in the lower half of the industry: LYRA underperforms 70.31% of its industry peers.
There is no outstanding debt for LYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.49 |
ROIC/WACCN/A
WACC9.05%
2.3 Liquidity
A Current Ratio of 3.60 indicates that LYRA has no problem at all paying its short term obligations.
LYRA has a Current ratio (3.60) which is comparable to the rest of the industry.
A Quick Ratio of 3.60 indicates that LYRA has no problem at all paying its short term obligations.
The Quick ratio of LYRA (3.60) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
The earnings per share for LYRA have decreased by -2.60% in the last year.
LYRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 46.45%.
Measured over the past years, LYRA shows a small growth in Revenue. The Revenue has been growing by 4.67% on average per year.
EPS 1Y (TTM)-2.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-131.25%
Revenue 1Y (TTM)46.45%
Revenue growth 3YN/A
Revenue growth 5Y4.67%
Sales Q2Q%30.57%
3.2 Future
LYRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.58% yearly.
The Revenue is expected to grow by 135.12% on average over the next years. This is a very strong growth
EPS Next Y-8.69%
EPS Next 2Y18.02%
EPS Next 3Y12.68%
EPS Next 5Y10.58%
Revenue Next Year0.51%
Revenue Next 2Y-36.26%
Revenue Next 3Y66.24%
Revenue Next 5Y135.12%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LYRA. In the last year negative earnings were reported.
Also next year LYRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LYRA's earnings are expected to grow with 12.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y12.68%
5. Dividend
5.1 Amount
No dividends for LYRA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LYRA THERAPEUTICS INC
NASDAQ:LYRA (11/21/2024, 8:00:01 PM)
After market: 0.1846 +0 (+1.48%)0.1819
+0 (+2.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.91M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.2% | ||
| ROE | -327.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-2.6%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-8.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)46.45%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y